Red Pine Resin Dosage Forms for Turpentine Side-Effect Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing medical uses of pine resin lack a defined dosage regime, leading to either no therapeutic benefit or severe side effects such as headache and hypertension due to varying turpentine content, limiting its effectiveness in treating type II diabetes and cancer.

Innovation Solution

A specific dosage regime for red pine resin with turpentine content ranging from 2.6 to 3.4% (w/w) is administered orally in forms like gels, capsules, or tablets, with doses between 500 mg and 12,000 mg, collected after 6-18 months to minimize side effects and enhance therapeutic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If pine resin is used without a defined dosage regime, then the turpentine content varies widely, but this leads to severe side effects such as headache and hypertension

Engineering Contradiction:

Improvedosage flexibilityVSAvoidside effects

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent establishes specific parameter ranges for turpentine content (2.6-3.4% w/w) and dosage (500-12,000 mg) to resolve the contradiction between dosage flexibility and side effect prevention. By defining these parameters, the patent enables versatile dosing while preventing the harmful effects associated with uncontrolled variation.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent implements a feedback mechanism by specifying that turpentine content should be measured and adjusted to fall within the 2.6-3.4% range. This feedback loop ensures that the resin is prepared and administered at optimal concentrations, preventing side effects while maintaining dosage adaptability.

Inventive Principle:

Principle #23Feedback

2Adaptability or versatility

If pine resin is used without a defined dosage regime, then dosage can be adjusted freely, but this results in no therapeutic benefit due to improper dosing

Engineering Contradiction:

Improvedosage adjustmentVSAvoidtherapeutic effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent defines specific parameter ranges for turpentine content (2.6-3.4% w/w) and dosage (500-12,000 mg) to ensure both dosage adaptability and therapeutic reliability. These parameters enable clinicians to adjust dosing while guaranteeing effective treatment outcomes.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent enables dynamic dosage adjustment within defined boundaries (500-12,000 mg), allowing the treatment to be adapted to individual patient needs while maintaining therapeutic effectiveness through the specified turpentine content range.

Inventive Principle:

Principle #15Dynamics

3Reliability

If high turpentine content resin is used, then the resin has strong therapeutic activity, but this causes hypertension and headache as side effects

Engineering Contradiction:

Improvetherapeutic activityVSAvoidhypertension and headache

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent identifies and applies the critical parameter of turpentine content, setting it within the optimal range of 2.6-3.4% w/w. This parameter optimization maintains strong therapeutic activity for treating type II diabetes and cancer while preventing hypertension and headache side effects associated with higher concentrations.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a standardized model of red pine resin with specific turpentine content (2.6-3.4%), which can be replicated consistently. This standardized copy ensures therapeutic effectiveness while eliminating the harmful effects of variable or excessive turpentine content.

Inventive Principle:

Principle #26Copying

4Reliability

If red pine resin is collected immediately after secretion, then the turpentine content is high providing strong therapeutic effect, but this also increases the risk of side effects

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects from high turpentine

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by allowing the red pine resin to mature for 6-18 months after secretion before use. This pre-treatment process naturally reduces excessive turpentine content to the optimal 2.6-3.4% range, ensuring therapeutic effectiveness while preventing side effects.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent utilizes the natural parameter change that occurs during the 6-18 month maturation period of red pine resin. Over time, the turpentine content decreases from high initial levels to the optimal therapeutic range of 2.6-3.4%, simultaneously maintaining efficacy and reducing side effects.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP3744338B1Medical uses of red pine resin and dosage forms therof

Publication Date: 2025.10.01 TEKDEMIR CANSEVEN

AI summary

The present invention relates to the medical uses of red pine resin. More particularly, the invention relates to uses and dosage forms of red pine (Pinus brutia) resin comprising turpentine, which is derived from red pine (calabrian pine) trees that grow at Aegean and Mediterranean regions of Turkey. Red pine resin is provided for use in the treatment of type II diabetes and/or cancer.